Hoxton Farms

Executive Summary

Hoxton Farms is a UK-based synthetic biology company developing cultivated animal fat for applications in cell therapy and food technology. Founded in 2020 and headquartered in London, the company leverages precision fermentation to produce sustainable, cruelty-free fat that mimics the functional and nutritional properties of traditional animal fat. Its core technology addresses key challenges in the cultured meat industry—such as flavor, texture, and scalability—while also providing biomaterials for therapeutic uses. Currently in the preclinical stage, Hoxton Farms operates with a lean team of 1–50 employees and is positioning itself at the intersection of regenerative medicine and the alternative protein market. By focusing on fat as a critical component, Hoxton Farms aims to enable the production of more realistic and cost-effective cell-cultured meat, as well as support the development of advanced cell therapies requiring specialized lipid-based environments. The company's multi-sector approach differentiates it from peers that focus solely on food or biomedicine. With the global cultivated meat market projected to grow rapidly and increasing regulatory support for cellular agriculture, Hoxton Farms is well-placed to capitalize on this tailwind. However, as a preclinical-stage private company with no disclosed funding or valuation, it faces significant technical and commercial risks before reaching market readiness. The company's success hinges on demonstrating its fat's equivalency to animal-derived fat at scale and securing partnerships with cultured meat producers and cell therapy firms.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Announcement75% success
• Q4 2026Strategic Partnership with Cultured Meat Producer60% success
• Q3 2026Publication of Key Preclinical Data on Fat Functionality80% success